{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T17:32:20Z","timestamp":1793640740218,"version":"4.5.1"},"reference-count":24,"publisher":null,"issue":"6","license":[{"start":{"date-parts":[[2020,6,3]],"date-time":"2020-06-03T00:00:00Z","timestamp":1591142400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/lib.ossn.ru\/jour\/about\/editorialPolicies#openAccessPolicy"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Kardiologiia"],"abstract":"<jats:p>\n                    <jats:italic>Aim<\/jats:italic>\n                    To study the antianginal and heart rate slowing effects in patients with stable angina (SA) who failed to achieve the heart rate (HR) goal and were switched from the beta-blocker (BB) metoprolol tartrate to a combination of metoprolol tartrate and ivabradine.\n                    <jats:italic>Materials and methods<\/jats:italic>\n                    The study included 54 patients with SA not higher than functional class (FC) III (35 (64.8\u200a%) men and 19 (35.2\u200a%) women) aged 59 [48; 77] years. Prior to the study start and at 4 and 8 weeks of follow-up, electrocardiography (ECG) and 24-h ECG monitoring (24h-ECGM) were performed for all patients. The follow-up period duration was 8 weeks. The antianginal and heart rate slowing effects of therapy were clinically evaluated by a decrease in frequency of anginal attacks and patients\u2019 requirement for nitrates, a decrease in HR, and the effect on 24h-ECGM indexes characterizing myocardial ischemia. At the first stage, all patients were prescribed metoprolol tartrate (Egilok\u00ae, Egis, Hungary) 25\u2008mg twice a day. Patients with resting HR still higher than 70 bpm after 4 weeks of treatment were switched from metoprolol tartrate to a fixed ivabradine\/metoprolol combination (Implicor\u00ae, Servier, France) 5\u200a\/\u200a25\u2008mg twice a day. Thus, based on achieving\/ non-achieving the HR goal, two groups of patients were formed. Statistical analysis was performed with a STATISTICA 10,0 software package.\n                    <jats:italic>Results<\/jats:italic>\n                    After 4 weeks of therapy with metoprolol tartrate 25 mg twice a day, 18 (33.3%) patients of group 1 achieved the HR goal of 70 bpm, while \u200836 (66.7%) patients of group 2 did not achieve the goal. For further correction of HR, patients of group 2 were switched from metoprolol tartrate to ivabradine\/metoprolol 5\u200a\/\u200a25\u2008mg twice a day. After 4 weeks of the ivabradine\/metoprolol treatment, 31 (86.1\u200a%) patients achieved the HR goal with median resting HR of 62 [56; 70] bpm. The number of angina attacks decreased from 6 [3; 8] to 2 [1; 3] per week (\u0440&lt;0.001). 24hECGM showed that the mean diurnal HR decreased from 81 [76; 96] to 66 [56; 76] bpm (\u0440&lt;0.001); mean night HR decreased from 69 [73; 80] to 52 [43; 60] bpm (\u0440=0.012); and the ischemic ST segment depression was absent.\n                    <jats:italic>Conclusion<\/jats:italic>\n                    Only 33.3% of patients with stable angina achieved the HR goal on metoprolol tartrate 25 mg twice a day. Supplementing the beta-blocker metoprolol tartrate at the same dose with ivabradine allowed 86.1% of patients to achieve the HR goal and exerted a pronounced anti-anginal effect.\n                  <\/jats:p>","DOI":"10.18087\/cardio.2020.6.n1135","type":"journal-article","created":{"date-parts":[[2020,7,28]],"date-time":"2020-07-28T06:23:16Z","timestamp":1595917396000},"page":"47-52","source":"Crossref","is-referenced-by-count":0,"title":["New opportunities to improve the treatment effectiveness of patients with stable angina"],"prefix":"10.68900","volume":"60","author":[{"given":"N. Yu.","family":"Grigoryeva","sequence":"first","affiliation":[{"name":"Federal State Budgetary Educational Institution of Higher Education \u00abPrivolzhsky Research Medical University\u00bb of the Ministry of Health of the Russian Federation, Nizhny Novgorod"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O. E.","family":"Vilkova","sequence":"additional","affiliation":[{"name":"Federal State Budgetary Educational Institution of Higher Education \u00abPrivolzhsky Research Medical University\u00bb of the Ministry of Health of the Russian Federation, Nizhny Novgorod"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. O.","family":"Samolyuk","sequence":"additional","affiliation":[{"name":"Federal State Budgetary Educational Institution of Higher Education \u00abPrivolzhsky Research Medical University\u00bb of the Ministry of Health of the Russian Federation, Nizhny Novgorod"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K. S.","family":"Kolosova","sequence":"additional","affiliation":[{"name":"Federal State Budgetary Educational Institution of Higher Education \u00abPrivolzhsky Research Medical University\u00bb of the Ministry of Health of the Russian Federation, Nizhny Novgorod"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":null,"published-online":{"date-parts":[[2020,6,3]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","unstructured":"Beautiful Study Group, Ferrari R, Ford I, Fox K, Steg PG, Tendera M. The BEAUTIFUL Study: Randomized Trial of Ivabradine in Patients with Stable Coronary Artery Disease and Left Ventricular Systolic Dysfunction \u2013 Baseline Characteristics of the Study Population. Cardiology. 2008;110(4):271\u201382. DOI: 10.1159\/000112412","DOI":"10.1159\/000112412"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Fox K, Ford I, Steg PG, Tendera M, Ferrari R. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. The Lancet. 2008;372(9641):807\u201316. DOI: 10.1016\/S0140-6736(08)61170-8","DOI":"10.1016\/S0140-6736(08)61170-8"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M et al. 2018 ESC\/ESH Guidelines for the management of arterial hypertension. European Heart Journal. 2018;39(33):3021\u2013104. DOI: 10.1093\/eurheartj\/ehy339","DOI":"10.1093\/eurheartj\/ehy339"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Knuuti J, Wijns W, Saraste A, Capodanno D, Barbato E, FunckBrentano C et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. European Heart Journal. 2020;41(3):407\u201377. DOI: 10.1093\/eurheartj\/ehz425","DOI":"10.1093\/eurheartj\/ehz425"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"Jones DA, Timmis A, Wragg A. Novel drugs for treating angina. BMJ. 2013;347:f4726. DOI: 10.1136\/bmj.f4726","DOI":"10.1136\/bmj.f4726"},{"key":"ref6","unstructured":"Gilyarevskiy S.R., Golshmid M.V., Kuzmina I.M. Validity of the use of \u03b2-blockers in patients with chronic coronary heart disease: scientific data and clinical practice. Atmosphere. Cardiology news. 2015;3:30\u20137."},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Forslund L, Hjemdahl P, Held C, Bj\u00f6rkander I, Eriksson SV, Brodin U et al. Prognostic implications of results from exercise testing in patients with chronic stable angina pectoris treated with metoprolol or verapamil. A report from The Angina Prognosis Study In Stockholm (APSIS). European Heart Journal. 2000;21(11):901\u201310. DOI: 10.1053\/euhj.1999.1936","DOI":"10.1053\/euhj.1999.1936"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"von Arnim T. Medical treatment to reduce total ischemic burden: Total ischemic burden bisoprolol study (TIBBS), a multicenter trial comparing bisoprolol and nifedipine. Journal of the American College of Cardiology. 1995;25(1):231\u20138. DOI: 10.1016\/0735-1097(94)00345-Q","DOI":"10.1016\/0735-1097(94)00345-Q"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet. 1999;353(9146):9\u201313","DOI":"10.1016\/S0140-6736(98)11181-9"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Effect of metoprolol CR\/XL in chronic heart failure: Metoprolol CR\/XL Randomised Intervention Trial in-Congestive Heart Failure (MERIT-HF). Lancet. 1999;353(9169):2001\u20137. DOI: 10.1016\/S0140-6736(99)04440-2","DOI":"10.1016\/S0140-6736(99)04440-2"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Packer M, Coats AJS, Fowler MB, Katus HA, Krum H, Mohacsi P et al. Effect of Carvedilol on Survival in Severe Chronic Heart Failure. New England Journal of Medicine. 2001;344(22):1651\u20138. DOI: 10.1056\/NEJM200105313442201","DOI":"10.1056\/NEJM200105313442201"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Flather MD, Shibata MC, Coats AJS, Van Veldhuisen DJ, Parkhomenko A, Borbola J et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). European Heart Journal. 2005;26(3):215\u201325. DOI: 10.1093\/eurheartj\/ehi115","DOI":"10.1093\/eurheartj\/ehi115"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"Rasmussen DB, Bodtger U, Lamberts M, Nicolaisen SK, Sessa M, Capuano A et al. Beta-blocker, aspirin, and statin usage after first-time myocardial infarction in patients with chronic obstructive pulmonary disease: a nationwide analysis from 1995 to 2015 in Denmark. European Heart Journal - Quality of Care and Clinical Outcomes. 2020;6(1):23\u201331. DOI: 10.1093\/ehjqcco\/qcy063","DOI":"10.1093\/ehjqcco\/qcy063"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. European Heart Journal. 2016;37(27):2129\u2013200. DOI: 10.1093\/eurheartj\/ehw128","DOI":"10.1093\/eurheartj\/ehw128"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"Zarifis J, Grammatikou V, Kallistratos M, Katsivas A, on Behalf of the Investigators of the Prospective, Noninterventional, Observational Study of the Antianginal Efficacy of Ivabradine During a 4-Month Treatment of a Greek Population with Coronary Artery Disease. Treatment of Stable Angina Pectoris with Ivabradine in Everyday Practice: A Pan-Hellenic, Prospective, Noninterventional Study: The antianginal efficacy of ivabradine. Clinical Cardiology. 2015;38(12):725\u201332. DOI: 10.1002\/clc.22479","DOI":"10.1002\/clc.22479"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"Amosova E, Andrejev E, Zaderey I, Rudenko U, Ceconi C, Ferrari R. Efficacy of Ivabradine in Combination with Beta-Blocker Versus Uptitration of Beta-Blocker in Patients with Stable Angina. Cardiovascular Drugs and Therapy. 2011;25(6):531\u20137. DOI: 10.1007\/s10557-011-6327-3","DOI":"10.1007\/s10557-011-6327-3"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"Kaski JC, Gloekler S, Ferrari R, Fox K, L\u00e9vy BI, Komajda M et al. Role of ivabradine in management of stable angina in patients with different clinical profiles. Open Heart. 2018;5(1):e000725. DOI: 10.1136\/openhrt-2017-000725","DOI":"10.1136\/openhrt-2017-000725"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"Fox K, Ford I, Steg PhG, Tendera M, Robertson M, Ferrari R et al. Relationship between ivabradine treatment and cardiovascular outcomes in patients with stable coronary artery disease and left ventricular systolic dysfunction with limiting angina: a subgroup analysis of the randomized, controlled BEAUTIFUL trial. European Heart Journal. 2009;30(19):2337\u201345. DOI: 10.1093\/eurheartj\/ehp358","DOI":"10.1093\/eurheartj\/ehp358"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"Zarifis J, Kallistratos M, Katsivas A, on behalf of the investigators of the Prospective, Non-interventional, Observational Study of the Antianginal Efficacy of Ivabradine During a 4-Month Treatment of a Greek Population with Coronary Artery Disease. Antianginal Efficacy of Ivabradine\/Metoprolol Combination in Patients with Stable Angina. Clinical Cardiology. 2016;39(12):697\u2013702. DOI: 10.1002\/clc.22585","DOI":"10.1002\/clc.22585"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"Zarifis J, Grammatikou V, Kallistratos M, Katsivas A. Antianginal Efficacy of Ivabradine in Patients with History of Coronary Revascularization. Angiology. 2017;68(1):10\u20138. DOI: 10.1177\/0003319716630499","DOI":"10.1177\/0003319716630499"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"Montalescot G, Sechtem U, Achenbach S, Andreotti F, Arden C, Budaj A et al. 2013 ESC guidelines on the management of stable coronary artery disease. Russian Journal of Cardiology. 2014;19(7):7\u201379. DOI: 10.15829\/1560-4071-2014-7-7-79","DOI":"10.15829\/1560-4071-2014-7-7-79"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"Rosenthal RL. The 50% Coronary Stenosis. The American Journal of Cardiology. 2015;115(8):1162\u20135. DOI: 10.1016\/j.amjcard.2015.01.553","DOI":"10.1016\/j.amjcard.2015.01.553"},{"key":"ref23","unstructured":"Global Initiative for Chronic Obstructive Lung Diseases (GOLD). Global strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. (2019 report). Av. at: https:\/\/goldcopd.org\/wp-content\/uploads\/2018\/11\/GOLD-2019-v1.7-FINAL-14Nov2018-WMS.pdf. 2019."},{"key":"ref24","unstructured":"Sujayeva V.A. Optimal medical therapy of stable angina:the place of an ivabradine - modern antianginal medicine. Medical news. 2018;1(280):55\u201360."}],"container-title":["Kardiologiia"],"original-title":[],"link":[{"URL":"https:\/\/lib.ossn.ru\/jour\/article\/viewFile\/1135\/714","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T17:17:37Z","timestamp":1793639857000},"score":1,"resource":{"primary":{"URL":"https:\/\/cardio.elpub.ru\/jour\/article\/view\/1135"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,3]]},"references-count":24,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2020,6,3]]}},"URL":"https:\/\/doi.org\/10.18087\/cardio.2020.6.n1135","relation":{},"ISSN":["2412-5660","0022-9040"],"issn-type":[{"value":"2412-5660","type":"electronic"},{"value":"0022-9040","type":"print"}],"subject":[],"published":{"date-parts":[[2020,6,3]]}}}